keyword
MENU ▼
Read by QxMD icon Read
search

non-small cell lung cacer

keyword
https://www.readbyqxmd.com/read/26045797/biomarkers-of-erlotinib-response-in-non-small-cell-lung-cancer-tumors-that-do-not-harbor-the-more-common-epidermal-growth-factor-receptor-mutations
#1
Blanca D López-Ayllón, Javier de Castro-Carpeño, Carlos Rodriguez, Olga Pernía, Inmaculada Ibañez de Cáceres, Cristobal Belda-Iniesta, Rosario Perona, Leandro Sastre
Non-small cell lung cancer (NSCLC) represents approximately 85% of all lung cancers, which are the leading cause of cancer-related deaths in the world. Tyrosine kinase inhibitors such as erlotinib represent one therapeutic options presently recommended for tumors produced by activating mutations in the gene coding of epidermal growth factor receptor (EGFR). The aim of this study is the identification of possible biomarkers for tumor sensitivity to erlotinib in the absence of the main EGFR mutations. The erlotinib sensitivity of cells isolated from 41 untreated NSCLC patients was determined and compared with the presence of the more frequent EGFR mutations...
2015: International Journal of Clinical and Experimental Pathology
https://www.readbyqxmd.com/read/26035979/primary-venous-and-malignancy-is-there-any-relationship
#2
Luis Cotto Santana, Williams Caceres Perkins
UNLABELLED: Deep venous thrombosis and pulmonary embolism can be the first manifestation of cancer. In light of this association screening for cancer has been proposed in patients with primary VTE to identify an undiagnosed malignancy. METHOD: Descriptive, retrospective record review that includes 3244 patients from VA San Juan Caribbean system with diagnosis of lung (small and non-small cell), prostate, colon, rectum, liver, stomach, esophagus, pancreas and breast cancer, lymphoma or leukemia from 2005 to 2010 evaluated for primary VTE during five years prior to their malignancy diagnosis...
January 2015: Boletín de la Asociación Médica de Puerto Rico
https://www.readbyqxmd.com/read/25482372/methylation-status-of-igfbp-3-as-a-useful-clinical-tool-for-deciding-on-a-concomitant-radiotherapy
#3
Olga Pernía, Cristobal Belda-Iniesta, Veronica Pulido, María Cortes-Sempere, Carlos Rodriguez, Olga Vera, Javier Soto, Julia Jiménez, Alvaro Taus, Federico Rojo, Edurne Arriola, Ana Rovira, Joan Albanell, M Teresa Macías, Javier de Castro, Rosario Perona, Inmaculada Ibañez de Caceres
The methylation status of the IGFBP-3 gene is strongly associated with cisplatin sensitivity in patients with non-small cell lung cancer (NSCLC). In this study, we found in vitro evidence that linked the presence of an unmethylated promoter with poor response to radiation. Our data also indicate that radiation might sensitize chemotherapy-resistant cells by reactivating IGFBP-3-expression through promoter demethylation, inactivating the PI3K/AKT pathway. We also explored the IGFBP-3 methylation effect on overall survival (OS) in a population of 40 NSCLC patients who received adjuvant therapy after R0 surgery...
November 2014: Epigenetics: Official Journal of the DNA Methylation Society
https://www.readbyqxmd.com/read/24961511/cancer-stem-cells-and-cisplatin-resistant-cells-isolated-from-non-small-lung-cancer-cell-lines-constitute-related-cell-populations
#4
Blanca D Lopez-Ayllon, Veronica Moncho-Amor, Ander Abarrategi, Inmaculada Ibañez de Cáceres, Javier Castro-Carpeño, Cristobal Belda-Iniesta, Rosario Perona, Leandro Sastre
Lung cancer is the top cause of cancer-related deceases. One of the reasons is the development of resistance to the chemotherapy treatment. In particular, cancer stem cells (CSCs), can escape treatment and regenerate the bulk of the tumor. In this article, we describe a comparison between cancer cells resistant to cisplatin and CSCs, both derived from the non-small-cell lung cancer cell lines H460 and A549. Cisplatin-resistant cells were obtained after a single treatment with the drug. CSCs were isolated by culture in defined media, under nonadherent conditions...
October 2014: Cancer Medicine
https://www.readbyqxmd.com/read/24102516/synthesis-and-chemical-and-biological-comparison-of-nitroxyl-and-nitric-oxide-releasing-diazeniumdiolate-based-aspirin-derivatives
#5
COMPARATIVE STUDY
Debashree Basudhar, Gaurav Bharadwaj, Robert Y Cheng, Sarthak Jain, Sa Shi, Julie L Heinecke, Ryan J Holland, Lisa A Ridnour, Viviane M Caceres, Regina C Spadari-Bratfisch, Nazareno Paolocci, Carlos A Velázquez-Martínez, David A Wink, Katrina M Miranda
Structural modifications of nonsteroidal anti-inflammatory drugs (NSAIDs) have successfully reduced the side effect of gastrointestinal ulceration without affecting anti-inflammatory activity, but they may increase the risk of myocardial infarction with chronic use. The fact that nitroxyl (HNO) reduces platelet aggregation, preconditions against myocardial infarction, and enhances contractility led us to synthesize a diazeniumdiolate-based HNO-releasing aspirin and to compare it to an NO-releasing analogue...
October 24, 2013: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/22613334/-efficacy-of-gemcitabine-and-vinorelbine-in-first-line-treatment-with-advanced-non-small-cell-lung-cancer-a-multicentre-retrospective-study
#6
MULTICENTER STUDY
Yongfeng Yu, Li Zhang, Zhisheng Ren, Jiujun Zhao, Zhongrui Li, Shun Lu
BACKGROUND AND OBJECTIVE: Chemotherapy has become the mainstay of first-line therapy. Non-platinum containing drugs are characterized by favorable toxicity profiles and is better tolerated than platinum-based regimens. The aim of this study is to detect the efficacy and toxicity of gemcitabine and vinorelbine (GN) in advanced non-small cell lung cancer (NSCLC) first-line treatment in China. METHODS: We retrospectively reviewed 67 NSCLC patients treated with this agent at five Hospital in China from Jan 2004 to Jun 2010...
May 2012: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/22543588/igfbp-3-methylation-derived-deficiency-mediates-the-resistance-to-cisplatin-through-the-activation-of-the-igfir-akt-pathway-in-non-small-cell-lung-cancer
#7
M Cortés-Sempere, M P de Miguel, O Pernía, C Rodriguez, J de Castro Carpeño, M Nistal, E Conde, F López-Ríos, C Belda-Iniesta, R Perona, I Ibanez de Caceres
Although many cancers initially respond to cisplatin (CDDP)-based chemotherapy, resistance frequently develops. Insulin-like growth factor-binding protein-3 (IGFBP-3) silencing by promoter methylation is involved in the CDDP-acquired resistance process in non-small cell lung cancer (NSCLC) patients. Our purpose is to design a translational-based profile to predict resistance in NSCLC by studying the role of IGFBP-3 in the phosphatidyl inositol 3-kinase (PI3K) signaling pathway. We have first examined the relationship between IGFBP-3 expression regulated by promoter methylation and activation of the epidermal growth factor receptor (EGFR), insulin-like growth factor-I receptor (IGFIR) and PI3K/AKT pathways in 10 human cancer cell lines and 25 NSCLC patients with known IGFBP-3 methylation status and response to CDDP...
March 7, 2013: Oncogene
https://www.readbyqxmd.com/read/20890299/dusp1-mkp1-promotes-angiogenesis-invasion-and-metastasis-in-non-small-cell-lung-cancer
#8
V Moncho-Amor, I Ibañez de Cáceres, E Bandres, B Martínez-Poveda, J L Orgaz, I Sánchez-Pérez, S Zazo, A Rovira, J Albanell, B Jiménez, F Rojo, C Belda-Iniesta, J García-Foncillas, R Perona
DUSP1/MKP1 is a dual-specific phosphatase that regulates MAPKs activity, with an increasingly recognized role in tumor biology. To understand more about the involvement of DUSP1 in lung cancer, we performed gene expression analyses of parental and DUSP1-interfered H460 non-small-cell lung cancer (NSCLC) cells. Downregulation of DUSP1 induced changes in the expression levels of genes involved in specific biological pathways, including angiogenesis, MAP kinase phosphatase activity, cell-cell signaling, growth factor and tyrosine-kinase receptor activity...
February 10, 2011: Oncogene
https://www.readbyqxmd.com/read/20363952/metabolism-and-disposition-of-14c-bms-690514-after-oral-administration-to-rats-rabbits-and-dogs
#9
Haizheng Hong, Hong Su, Haojun Sun, Alban Allentoff, Ihoezo V Ekhato, Theodore Chando, Janet Caceres-Cortes, Vikram Roongta, Ramaswamy A Iyer, W Griffith Humphreys, Lisa J Christopher
(3R,4R)-4-Amino-1-((4-((3-methoxyphenyl)amino)pyrrolo[2,1-f] [1,2,4]triazin-5-yl)methyl)-3-piperidinol (BMS-690514) is a potent inhibitor of human epidermal growth factor receptors 1, 2, and 4 and vascular endothelial growth factor receptors 1 through 3. BMS-690514 is an oral oncologic agent currently being developed for the treatment of patients with advanced non-small cell lung cancer and breast cancer. In this investigation, a series of studies was conducted to determine the biotransformation of [(14)C]BMS-690514 after oral administration to rats, rabbits, and dogs...
July 2010: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/20023704/igfbp-3-hypermethylation-derived-deficiency-mediates-cisplatin-resistance-in-non-small-cell-lung-cancer
#10
I Ibanez de Caceres, M Cortes-Sempere, C Moratilla, R Machado-Pinilla, V Rodriguez-Fanjul, C Manguán-García, P Cejas, F López-Ríos, L Paz-Ares, J de CastroCarpeño, M Nistal, C Belda-Iniesta, R Perona
Cisplatin-based chemotherapy is the paradigm of non-small-cell lung cancer (NSCLC) treatment; however, it also induces de novo DNA-hypermethylation, a process that may be involved in the development of drug-resistant phenotypes by inactivating genes required for drug-cytotoxicity. By using an expression microarray analysis, we aimed to identify those genes reactivated in a set of two cisplatin (CDDP) resistant and sensitive NSCLC cell lines after epigenetic treatment. Gene expression, promoter methylation and CDDP-chemoresponse were further analyzed in three matched sets of sensitive/resistant cell lines, 23 human cancer cell lines and 36 NSCLC specimens...
March 18, 2010: Oncogene
https://www.readbyqxmd.com/read/18301774/vilip-1-downregulation-in-non-small-cell-lung-carcinomas-mechanisms-and-prediction-of-survival
#11
Jian Fu, Kathryn Fong, Alfonso Bellacosa, Eric Ross, Sinoula Apostolou, Daniel E Bassi, Fang Jin, Jirong Zhang, Paul Cairns, Inmaculada Ibañez de Caceres, Karl-Heinz Braunewell, Andres J Klein-Szanto
VILIP-1, a member of the neuronal Ca++ sensor protein family, acts as a tumor suppressor gene in an experimental animal model by inhibiting cell proliferation, adhesion and invasiveness of squamous cell carcinoma cells. Western Blot analysis of human tumor cells showed that VILIP-1 expression was undetectable in several types of human tumor cells, including 11 out of 12 non-small cell lung carcinoma (NSCLC) cell lines. The down-regulation of VILIP-1 was due to loss of VILIP-1 mRNA transcripts. Rearrangements, large gene deletions or mutations were not found...
2008: PloS One
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"